Valion Bio Inc (VBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valion Bio Inc (VBIO) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($16.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VBIO equity financing ratio to measure how much of total assets are equity-financed.
Valion Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Valion Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VBIO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Valion Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valion Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Energy Metals Corp
V:GEMC
|
-0.028x |
|
Baumart Holdings Ltd
AU:BMH
|
-0.258x |
|
Lucibel
PA:ALUCI
|
6.802x |
|
Avation PLC
LSE:AVAP
|
-0.005x |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
0.049x |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
0.220x |
|
Visionary Education Technology Holdings Group Inc.
NASDAQ:GV
|
-0.351x |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Valion Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Valion Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Valion Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -32.17% |
| 2020-12-31 | $863.39K | $-1.61 Million | -1.859x | +33.60% |
| 2019-12-31 | $1.28 Million | $-3.59 Million | -2.800x | +68.74% |
| 2017-12-31 | $322.27K | $-2.89 Million | -8.957x | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more